Ticagrelor Tablet
Product Images NDC 60687-935

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 60687-935). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

90 mg Ticagrelor Tablet Blister.jpg (90 mg Ticagrelor Tablet Blister)

Ticagrelor 90 mg oral tablet labels from American Health Packaging. Each label includes the product name, strength, dosage form, barcode, and manufacturer information. Expiration date and lot number fields are shown but not filled in.*

FDA Label Image

90 mg Ticagrelor Tablets Carton.jpg (90 mg Ticagrelor Tablets Carton)

Ticagrelor 90 mg oral tablets label showing packaging information for 60 tablets (6 x 10), labeled for prescription use only. The label includes NDC number 60687-928-57 and states that each tablet contains 90 mg of Ticagrelor. Storage instructions, dispensing guidance, and distributor information (American Health Packaging) are also visible. A QR code for medication guide and prescribing information is present.*

FDA Label Image

Figure1.jpg (Figure1)

A line graph showing cumulative percentage over days from first study drug dose up to 360 days, comparing Ticagrelor 90 mg (solid line) and Clopidogrel (dashed line). The x-axis represents days, and the y-axis shows cumulative percentage. A legend box details patient numbers and event rates for each drug, with Ticagrelor having 9235 patients and 4.5% KM events at 12 months, and Clopidogrel 9186 patients with 3.8% KM events. A risk table below shows patient counts at intervals for both treatments.*

FDA Label Image

Figure10.jpg (Figure10)

A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg and Clopidogrel over 360 days from randomization. The y-axis shows cumulative percentage, and the x-axis shows days. The graph includes sample sizes, event percentages, hazard ratio with confidence interval, and p-value in a legend. Patient numbers at risk are provided below the x-axis over time.*

FDA Label Image

Figure11.jpg (Figure11)

A forest plot comparing the treatment effects of Ticagrelor versus Clopidogrel across various patient characteristics and subgroups. The horizontal axis shows hazard ratios (HR) with confidence intervals (CI), indicating results favoring Ticagrelor on the left and Clopidogrel on the right. Subgroups include geographic region, aspirin dose, treatment approach, early PCI, CABG status, diabetes history, prior stroke, use of Glycoprotein IIb/IIIa inhibitor, age group, sex, and race.*

FDA Label Image

Figure12.jpg (Figure12)

A forest plot comparing the effectiveness of Ticagrelor versus Clopidogrel across different regions (US and Non-US) and aspirin dose ranges. The plot shows hazard ratios (HR) with 95% confidence intervals (CI) for each subgroup, indicating relative treatment effects between the two drugs.*

FDA Label Image

Figure13.jpg (Figure13)

A Kaplan-Meier cumulative percentage curve illustrating event occurrence over days from randomization for Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups. Data points show the cumulative percentage on the y-axis and days on the x-axis up to approximately 1320 days, with tables indicating numbers at risk and statistical values including hazard ratios and p-values for each group.*

FDA Label Image

Figure14.jpg (Figure14)

A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus placebo across various patient subgroups and characteristics. The plot includes treatment effects by age, sex, race, weight, BMI, geographic region, MI history, diabetes, coronary artery disease, kidney function, stent type, smoking status, and previous treatment timelines. Each subgroup displays event rates and HR values indicating the relative benefit of Ticagrelor over placebo.*

FDA Label Image

Figure15.jpg (Figure15)

A Kaplan-Meier cumulative incidence curve showing cumulative percentage (%) over months from randomization up to 54 months, comparing Ticagrelor (solid line) versus Placebo (dashed line). The graph includes event counts and sample sizes for each group and a risk table beneath outlining the number at risk over time.*

FDA Label Image

Figure16.jpg (Figure16)

A forest plot comparing hazard ratios (HR) and 95% confidence intervals (CI) for various patient characteristics between Ticagrelor and placebo groups. The plot visually represents the effect sizes and confidence intervals for subgroups defined by age, sex, race, BMI, geographic region, aspirin dose, HbA1c levels, kidney function, insulin use, and cardiac history among others.*

FDA Label Image

Figure17.jpg (Figure17)

A Kaplan-Meier cumulative percentage curve graph comparing Ticagrelor 90 mg twice daily (bd) to placebo over approximately 34 days from randomization. The y-axis shows cumulative percentage up to 8%, and the x-axis shows days from randomization. The graph includes event counts and sample sizes (303/5523 for Ticagrelor, 362/5493 for placebo) along with patient numbers at risk over time for each group.*

FDA Label Image

Figure18.jpg (Figure18)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals (CI) between Ticagrelor and placebo across various patient characteristics. The chart shows subgroup analyses by age, sex, race, weight, BMI, geographic region, diagnosis, and other clinical factors, illustrating the relative effect of Ticagrelor versus placebo on an unspecified outcome.*

FDA Label Image

Figure2.jpg (Figure2)

A bar chart depicting the percentage of patients who had an event following coronary artery bypass grafting (CABG) over various days. The x-axis shows days post-CABG with corresponding patient counts labeled T and C below each day. The y-axis shows the percentage scale from 0 to 100. Bars compare two groups labeled T (solid black) and C (hatched) across days 1 to 8 and beyond, illustrating event percentages for each group over time.*

FDA Label Image

Figure3.jpg (Figure3)

A cumulative percentage line graph comparing Ticagrelor and placebo over 54 months from randomization. The Y-axis shows cumulative percentage (%) and the X-axis shows months. The solid line represents Ticagrelor with higher cumulative events than the dashed line representing placebo. The chart includes numbers at risk for each group over time and the number of events out of total participants for both groups.*

FDA Label Image

Figure4.jpg (Figure4)

A Kaplan-Meier cumulative percentage curve graph showing events over days from randomization comparing Ticagrelor 90 mg twice daily (solid line) versus placebo (dashed line). The x-axis represents days from randomization (0 to 34), and the y-axis shows cumulative percentage (0 to 1.0). Numbers at risk for each group are listed below the x-axis.*

FDA Label Image

Figure5.jpg (Figure5)

A line graph comparing IPA (%) induced by 202m ADP over time (hours) among three groups: Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo. The graph shows Ticagrelor with the highest IPA levels sustained over 8 hours, Clopidogrel with intermediate IPA levels, and Placebo with the lowest IPA values throughout the time course.*

FDA Label Image

Figure6.jpg (Figure6)

A line graph displaying IPA (%) induced by 20 mcM ADP over time, with the x-axis labeled "Time (day)" and y-axis labeled "IPA (%) Induced by 20 mcM ADP." Three different data series are represented with distinct markers (circles, triangles, squares). An inset graph shows a similar plot over a shorter timeframe labeled "Time (hour)." The chart illustrates changes in IPA percentage response to ADP stimulation across multiple days and hours.*

FDA Label Image

Figure7.jpg (Figure7)

A forest plot displaying the mean effect and 90% confidence interval for Ticagrelor across various intrinsic factors including age, gender, ethnicity, renal and hepatic impairment. The plot compares pharmacokinetic measures Cmax and AUC between different subgroups, with dose adjustment recommendations noted as 'No dose adjustment' for all factors.*

FDA Label Image

Figure8.jpg (Figure8)

A chart titled 'Mean effect and 90% CI' showing the impact of various interacting drugs on Ticagrelor and AR-C124910XX. The graph plots change relative to reference on the x-axis, illustrating effects on pharmacokinetic parameters Cmax and AUC with labeled interacting drugs and corresponding clinical recommendations.*

FDA Label Image

Figure9.jpg (Figure9)

A forest plot chart illustrating the interaction effects of various drugs with different doses of Ticagrelor. The chart shows mean effect and 90% confidence intervals along with dose adjustment recommendations for each interacting drug, including Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure of ticagrelor, a human prescription drug used as an oral tablet available in 60 mg and 90 mg strengths. The image depicts the molecular formula with various functional groups including hydroxyl, fluorophenyl, and thienopyrimidine ring structures.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.